LLY•benzinga•
Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
Summary
Eli Lilly and Verge Genomics advance ALS drug development with validated targets and a Phase 1B study, part of their $694 million collaboration since 2021.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 20, 2024 by benzinga